Tanios Bekaii-Saab, MD: Experience With Patients on Bevacizumab Plus Chemotherapy
What is your experience with patients who receive bevacizumab plus a CT regimen? What types of issues/side effects do they report with treatment?
Bevacizumab is relatively safe to administer with chemotherapy. It doesn't seem to exacerbate or worsen the chemotherapy toxicities. It has its toxicities, like we said with hypertension, proteinuria, arterial thromboembolic events which are rare if you choose the right patients, and issues with bowel perforation which is also a rare event. Overall, adding bevacizumab to chemotherapy seems to be fairly safe as long as you select the right patients and you are careful about stopping the bevacizumab 4 to 6 weeks prior to surgical resection, and then starting again 4 to 6 weeks after surgery.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More
